Learn more →
Back to Expert Scholars
Immunotherapy / 免疫治疗Cancer Vaccines

Uğur Şahin

M.D.

🏢BioNTech / University of Mainz(BioNTech / 美因茨大学)🌐Germany

CEO and Co-founder, BioNTech

1
Key Papers
2
Awards
2
Key Contributions

👥Biography 个人简介

Uğur Şahin is a pioneer in mRNA therapeutics and personalized cancer vaccines. He co-founded BioNTech, which has advanced mRNA technology for both infectious disease vaccines and cancer immunotherapy. Şahin's work on individualized neoantigen mRNA vaccines has shown promising clinical results, demonstrating the potential of personalized cancer vaccination based on patient-specific tumor mutations.

Uğur Şahin是mRNA治疗和个性化癌症疫苗的先驱。他共同创立了BioNTech,该公司推进了用于传染病疫苗和癌症免疫治疗的mRNA技术。Şahin在个体化新抗原mRNA疫苗方面的工作显示了令人鼓舞的临床结果,展示了基于患者特异性肿瘤突变的个性化癌症疫苗接种的潜力。

Share:

🧪Research Fields 研究领域

mRNA VaccinesmRNA疫苗
Personalized Cancer Immunotherapy个性化癌症免疫治疗
Neoantigen Targeting新抗原靶向

🎓Key Contributions 主要贡献

mRNA Cancer Vaccines

Developed mRNA platform for personalized neoantigen cancer vaccines.

BioNTech Platform

Built integrated mRNA technology platform enabling rapid vaccine development.

Representative Works 代表性著作

[1]

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Nature (2017)

First demonstration of personalized mRNA neoantigen vaccine efficacy.

🏆Awards & Recognition 奖项与荣誉

🏆Mustafa Prize (2019)
🏆Paul Ehrlich and Ludwig Darmstaedter Prize (2022)

📄Data Sources 数据来源

Last updated: 2026-03-04 | All information from publicly available academic sources

关注 Uğur Şahin 的研究动态

Follow Uğur Şahin's research updates

留下邮箱,当我们发布与 Uğur Şahin(BioNTech / University of Mainz)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment